Toward Health Peptide and Hormone Therapy Guide

Benefits

Semaglutide can improve several aspects of metabolic health. It lowers blood sugar in type 2 diabetes and reduces heart attacks, strokes, or cardiovascular death in defined high-risk groups. For people with established cardiovascular disease and overweight or obesity without diabetes, these events occurred in 6.5% with semaglutide versus 8.0% with placebo. In type 2 diabetes with chronic kidney disease, it slows kidney-function loss and reduces serious kidney outcomes. It also treats MASH, the inflammatory form of fatty liver disease: in adults with moderate-to-advanced scarring but no cirrhosis, liver inflammation resolved without worsening scarring in about 63% versus 34%, and scarring improved without worsening MASH in 37% versus 22%. Whether this prevents liver failure or transplantation is still being studied. Other demonstrated benefits include improved symptoms and physical function in obesity-related heart failure with preserved ejection fraction, and less knee-arthritis pain in people with obesity. For weight management, the commonly studied weekly formulation produced average weight loss of about 15% over roughly 16 months in adults without diabetes. The appropriate product and expected benefit depend on the condition; these results do not mean every formulation treats every condition.

Safety

Shared GLP-1 risks and precautions

Semaglutide has a specific diabetic-retinopathy signal, especially during rapid improvement in blood sugar. European regulators also classify NAION as a very rare adverse effect; this is a different eye condition that can cause permanent vision loss.

Benefits

Liraglutide lowers blood sugar in type 2 diabetes and reduces major cardiovascular events in people with type 2 diabetes and established cardiovascular disease. It also supports weight loss and lowers the chance of progressing from prediabetes to diabetes while treatment continues. Its benefits extend beyond these established uses: it can modestly reduce sleep-apnea severity in people with obesity, although this is not an approved sleep-apnea indication or a guarantee that CPAP is no longer needed. Early biopsy evidence also supports improvement in MASH, the inflammatory form of fatty liver disease, but liraglutide is not an approved MASH treatment. Kidney findings are encouraging, particularly less development of substantial protein leakage into urine; prevention of kidney failure itself is less firmly established. The strongest reasons to choose liraglutide remain its demonstrated diabetes, cardiovascular, and weight-management benefits.

Safety

Shared GLP-1 risks and precautions

Liraglutide can increase resting heart rate; persistent palpitations or a racing heartbeat warrant review. Australian warnings also describe NAION reports, without establishing the same causal evidence as for semaglutide.

Benefits

Tirzepatide provides strong blood-sugar control in type 2 diabetes and can substantially improve obesity-related disease. For adults with obesity and moderate-to-severe obstructive sleep apnea, it reduces breathing interruptions and improves sleep-related symptoms; Zepbound is approved for this use. Some people improve to mild or no measurable apnea; follow-up determines whether other sleep-apnea treatment is still needed. Mounjaro also has a cardiovascular risk-reduction indication for adults with type 2 diabetes at high risk. In obesity-related heart failure with preserved ejection fraction, tirzepatide reduces worsening heart-failure events and improves symptoms and daily function. It also shows meaningful liver benefit in MASH: inflammation resolved without worsening scarring in 44–62% versus 10%, with improvement in scarring as well, although MASH is not an approved indication. Kidney-function findings are promising but come from secondary analyses. Average weight loss with tirzepatide reached roughly 15–21% over about 18 months, depending on the studied dose. It also markedly reduced progression from prediabetes to diabetes during continued treatment.

Safety

Shared GLP-1 risks and precautions

Tirzepatide can temporarily reduce the reliability of oral hormonal contraception when treatment starts or increases. In one body-composition substudy, roughly one-quarter of the weight lost was lean mass, which is not equivalent to skeletal-muscle loss or weakness.

Benefits

Retatrutide has demonstrated substantial glucose lowering in type 2 diabetes, improvement in obstructive sleep apnea, and less knee-arthritis pain in people with obesity. The measured benefits include fewer breathing interruptions during sleep and less arthritis pain. It also markedly reduces liver fat on MRI. That liver-fat response is promising for fatty liver disease, but it does not establish resolution of MASH inflammation, reversal of scarring, or prevention of liver failure. Mean weight loss reached 25% at 80 weeks in phase 3 research, alongside these condition-specific benefits. It remains investigational, and reductions in heart attacks, strokes, kidney failure, or mortality have not yet been established.

Safety

Shared GLP-1 risks and precautions

Retatrutide can cause dysesthesia: burning, tingling or painful skin sensitivity. In Lilly's 68-week TRIUMPH-4 report in people with obesity and knee osteoarthritis, this affected 8.8% at the 9 mg study dose and 20.9% at 12 mg, versus 0.7% on placebo. Treatment discontinuation because of adverse events was 12.2% and 18.2%, respectively, versus 4.0% on placebo. Those stopping rates include all adverse events, not just skin symptoms; Lilly described most sensory events as mild and rarely leading to discontinuation. In its larger TRIUMPH-1 report, 11.3% stopped the highest dose because of adverse events versus 4.9% on placebo. Selected continuing participants have about two years of exposure; uncommon and longer-term risks remain incompletely characterized.

Benefits

CagriSema improves blood-sugar control in type 2 diabetes and combines cagrilintide with semaglutide for weight management; average weight loss was about 20% over 68 weeks. It also lowers blood pressure, a useful cardiovascular risk factor, although a lower reading is not the same as demonstrated prevention of heart attacks or strokes. The combination's cardiovascular-outcome study is still needed to establish that benefit directly. Semaglutide's proven kidney and MASH benefits should not automatically be assigned to CagriSema: the combination needs its own evidence for those conditions. CagriSema remains investigational, with its strongest direct evidence currently in glucose control and weight management.

Safety

Shared GLP-1 risks and precautions

Digestive symptoms were reported by 79.6% versus 39.9% on placebo in REDEFINE 1; most were temporary and mild to moderate. Adverse events led 5.9% versus 3.5% to stop treatment. Serious adverse events occurred in 9.8% versus 6.1%, without establishing that treatment caused each event. The combination needs its own risk estimates and longer-term safety follow-up.

Benefits

Survodutide has direct evidence for improving fatty liver disease as well as blood-sugar control and weight. It reduces liver fat on MRI and can improve the inflammation and injury of MASH without worsening scarring. These are distinct findings: lower liver fat is an imaging improvement, whereas MASH improvement comes from liver biopsies. The evidence does not yet establish prevention of cirrhosis, liver failure, or transplantation. In adults with obesity and type 2 diabetes, survodutide also lowers A1c. It remains investigational, with liver disease a particularly important potential use; cardiovascular-event and kidney-failure prevention have not been demonstrated.

Safety

Shared GLP-1 risks and precautions

Digestive symptoms are a prominent treatment limitation. The controlled evidence identified here extends to about a year and a half, leaving uncommon harms and prolonged use less well characterized.

Benefits

Mazdutide improves blood-sugar control in type 2 diabetes and supports substantial weight loss. It is approved in China for weight management and type 2 diabetes, but not in the United States. Early imaging data also show considerable reductions in liver fat, suggesting potential value for fatty liver disease. That finding is not the same as proving that MASH inflammation or liver scarring resolves. Evidence for prevention of heart attacks, strokes, kidney failure, or liver complications is not yet established. Its current benefits should be described as glucose lowering, weight management, and promising liver-fat reduction rather than broad protection against every metabolic disease.

Safety

Shared GLP-1 risks and precautions

In a U.S. study, adverse events led about one in five participants at the highest studied dose to discontinue. Digestive symptoms are the main adverse effects. Longer and broader experience is still needed to characterize uncommon harms; a safety advantage over established U.S. obesity medicines has not been shown.

Benefits

Pemvidutide has promising direct evidence for treating MASH, the inflammatory form of fatty liver disease, in people with moderate-to-advanced liver scarring. Liver inflammation resolved without worsening scarring in about 52–58% of treated participants versus 20% with placebo at 24 weeks. Improvement in scarring itself was not clearly better than placebo at that point, so resolving inflammation should not be described as proven fibrosis reversal. Pemvidutide also reduces liver fat and body weight. It remains investigational; prevention of liver failure, transplantation, cardiovascular events, or kidney failure has not yet been established.

Safety

Shared GLP-1 risks and precautions

At the highest studied dose, approximately one in five participants stopped because of adverse events, versus about 6% on placebo; nausea and vomiting were prominent. Safety follow-up remains relatively short. No major cardiovascular events in a small study does not establish cardiovascular protection or exclude uncommon harm.

Benefits

Cagrilintide acts on appetite through the amylin pathway and produces meaningful weight loss when used alone. Controlled human evidence supports average reductions of roughly 10–12%, with the estimate depending on dose, duration and analysis. The effect is greater than placebo, but its benefit in preventing cardiovascular events or other obesity complications has not been established. It remains investigational, and its evidence should be distinguished from that for CagriSema, which combines it with semaglutide.

Safety

Nausea and other digestive symptoms are the most consistent adverse effects. Human experience is shorter and smaller than for established GLP-1 medicines, leaving uncommon risks and prolonged use incompletely characterized.

Benefits

Pramlintide can modestly improve blood-sugar control and help limit weight gain when added to mealtime insulin in selected people with type 1 or type 2 diabetes. It does not replace insulin. Some people lose weight, and separate obesity research also found modest reductions, but it is not an approved standalone obesity treatment. Its strongest evidence concerns its specific role alongside insulin; the weight-management evidence is less extensive than for modern approved obesity medicines.

Safety

Nausea is common, especially early in treatment. The central safety concern is severe low blood sugar when it is combined with insulin, particularly in type 1 diabetes. Safe use requires coordinated insulin adjustment and careful glucose monitoring. It should not be used in people who cannot reliably recognize hypoglycemia or who have confirmed gastroparesis. It also delays stomach emptying, which can affect the timing of other oral medicines.

Benefits

Tesamorelin reduces deep abdominal fat in adults with HIV-associated lipodystrophy. This is its established role; it is not a general weight-loss medicine and usually does not produce substantial overall weight loss. Imaging shows meaningful reductions in visceral fat during treatment, with the benefit tending to reverse after stopping. It has not been shown to prevent heart attacks or extend life. For ordinary obesity, approved weight-management treatments have more directly relevant evidence for total weight loss and associated health outcomes.

Safety

Joint or muscle discomfort, swelling, carpal-tunnel symptoms and injection-site reactions can occur. It raises IGF-1 and can worsen glucose tolerance or contribute to diabetes, so glucose and IGF-1 monitoring are important. Prolonged elevations of this growth factor have uncertain consequences. Active cancer, disruption of the hypothalamic-pituitary system and pregnancy are contraindications; a past cancer history requires particular consideration. Serious allergic reactions are possible. The controlled safety experience is mainly around one year, and long-term cardiovascular safety has not been established.

Benefits

Setmelanotide targets a specific brain pathway controlling hunger and can substantially reduce excessive hunger and weight in qualifying rare genetic obesity disorders and acquired hypothalamic obesity. The benefit depends on the diagnosis; it is not established treatment for common obesity. In acquired hypothalamic obesity, average BMI fell about 16.5% over a year, while it increased in the placebo group. Genetic-obesity evidence is smaller, with some participants followed for about three years. This is a targeted option for patients whose underlying condition fits, rather than a general substitute for established obesity medicines.

Safety

Injection-site reactions, skin darkening, nausea and other digestive symptoms are common. Important concerns include depression or suicidal thoughts, changes in sexual arousal and serious allergic reactions. Skin examinations matter because existing moles may darken and new pigmented lesions can appear. In people with acquired hypothalamic obesity, underlying adrenal insufficiency and sodium-balance problems require close attention; serious adrenal-insufficiency events have been reported more often with treatment. Its safety evidence is less extensive than that for commonly prescribed obesity medicines, especially within each rare diagnosis.

Benefits

AOD-9604 has not demonstrated reliable weight-loss benefit in people. The largest longer oral study failed to show a statistically significant advantage over placebo. This is negative human evidence, not merely a treatment waiting for its first study. Promising laboratory findings do not overcome that result, and there is no convincing repeated-injection evidence showing an effect comparable to approved obesity medicines.

Safety

Short human studies did not establish a consistent major safety signal, but adverse-event reporting was incomplete and long-term safety remains poorly characterized. Most available experience used oral treatment or brief intravenous exposure, which cannot establish the safety of repeated subcutaneous injections. FDA has also identified serious adverse events potentially associated with AOD-9604, although a causal relationship has not been established.

Human findings

The artery-imaging evidence is mixed. In a 26-week randomized comparison with simvastatin, 76 of 82 participants completed treatment. The study compared oral nattokinase at 6,000 fibrinolytic units (FU) daily with simvastatin at 20 mg daily. Carotid plaque area fell 36.6% with nattokinase versus 11.5% with simvastatin. Simvastatin produced larger reductions in LDL cholesterol, total cholesterol and triglycerides. The favorable plaque result is worth discussing, but it is one ultrasound endpoint, not evidence of better overall cardiovascular protection than statins. [2]

A 12-month retrospective report of 1,062 people, principally using 10,800 FU daily, also found improved lipids and carotid imaging, with artery measurements evaluated in the 683 participants with atherosclerosis. However, a double-blind trial of 2,000 FU daily in 265 adults without clinical cardiovascular disease found no improvement in carotid wall thickness or arterial stiffness after a median three years. These are study exposures, not a treatment schedule. The populations, exposures and designs differed. Those differences may help explain the disagreement, but they do not establish that a higher exposure reliably overcomes the negative result. [3] [4]

For blood pressure, an eight-week placebo-controlled trial found reductions of about 5.6 mmHg systolic and 2.8 mmHg diastolic relative to placebo; 73 of 86 participants completed it. Small changes in fibrinolysis are also measurable: a 12-person crossover study found several clotting and clot-breakdown markers changed over eight hours, while remaining within their usual reference ranges. This is evidence of biological activity, with a separate unanswered question about prevention of heart attacks or strokes. [5] [6]

A more recent six-month trial examined cognition in 120 people with asymptomatic intracranial or carotid narrowing. The primary global cognitive score did not improve compared with placebo. An exploratory visuospatial subscore favored nattokinase, providing a narrower question for future research rather than a general cognitive benefit. [7]

Laboratory findings & theoretical potential

Interest in spike-protein degradation comes from direct laboratory exposure. Nattokinase reduced detectable SARS-CoV-2 spike protein in cell lysates in a concentration- and time-dependent manner and reduced surface staining in engineered cultured cells. The enzyme also degraded other proteins, including ACE2 and GAPDH, so this was not selective spike targeting. The study did not test whether an oral supplement removes spike protein or improves long COVID, vaccine-related symptoms or acute infection in people. [8]

Adverse effects & interactions

Clinical studies have generally reported few major adverse events, including the 12-month retrospective report, but they are not large enough to give a dependable rate of uncommon bleeding. Serious bleeding has been described in case reports: one involved aspirin use and pre-existing cerebral microbleeds; another involved an older woman with kidney disease and a recent fall. These are signals to consider, with contributing factors that prevent assigning nattokinase the sole cause. The combination with medicines that reduce clotting deserves particular attention. [9] [10]

Safety findings also belong to the preparation studied. EFSA assessed a specified fermented-soybean extract for a defined adult food use, not every nattokinase product or every proposed medical use. The current U.S. regulatory distinction is similar: availability as a supplement is separate from approval to treat cardiovascular disease. These distinctions help interpret product claims without erasing the human findings. [11] [12]

Benefits

BPC-157 has not yet been shown to repair human tendons, ligaments or cartilage, or reliably speed recovery from an injury. Some people in small reports described less pain, but pain relief does not establish that damaged tissue healed or that the peptide caused the improvement. Animal findings are promising enough to investigate, but they do not tell us how much benefit a patient should expect. Diagnosis-specific rehabilitation and established orthopedic treatments have better-defined outcomes; BPC-157 has not demonstrated an advantage over them.

Safety

Human reports are too limited to reliably estimate common side effects, uncommon serious harms or the safety of repeated and long-term use. Potential concerns include immune reactions, impurities and uncertainty about the exact material being administered. Sterility is an additional concern for injections.

Benefits

There is no established human benefit for the seven-amino-acid TB-500 fragment in wound healing, tendon repair or return to sport. Research on full-length thymosin beta-4 concerns a different molecule and cannot establish that TB-500 works. This is primarily a gap in applicable evidence, rather than a completed clinical program showing the fragment does not work. Wound care should address blood supply, infection and pressure, while musculoskeletal injuries need appropriate diagnosis and rehabilitation.

Safety

Human safety is largely uncharacterized, including common side effects, serious reactions and risks from repeated exposure. Immune reactions and peptide impurities are concerns, particularly for injected products. Safety information from full-length thymosin beta-4 should not be transferred to the TB-500 fragment.

Human findings

For bladder symptoms, a randomized trial in 96 adults with bladder-centered symptoms compared intravesical DMSO with placebo over 12 weeks. The symptom index improved by 5.2 versus 3.4 points, a between-group difference of 1.8 points. Overall patient-reported response also favored DMSO, although the separate pain-score difference was not statistically significant at week 12. [2] An earlier 33-person crossover study likewise found more symptomatic improvement with DMSO than saline. [3]

For knee osteoarthritis, a three-week trial of 112 people reported less pain with topical DMSO gel. [4] A later 775-person, five-arm trial found no advantage of its DMSO vehicle over placebo at 12 weeks; benefit belonged to the diclofenac-containing treatment. The pain evidence is inconsistent. [5]

The basal-cell study enrolled 25 people with 29 lesions. At eight weeks, biopsy clearance occurred in 13/15 lesions with topical vitamin C plus DMSO versus 8/14 with imiquimod. The trial tested the combination, without a DMSO-only arm; it was not a comparison with surgery. [6]

A separate 2025 preprint reported clearance of 15/27 squamous-cell carcinoma-in-situ lesions among 17 analyzed participants after 12 weeks. Nineteen enrolled, two were lost to follow-up, and there was no control group. The current source remains labeled a preprint; no peer-reviewed replacement was identified. Clearance, lesion shrinkage and subsequently avoiding surgery are different outcomes. [7]

Laboratory findings & theoretical potential

One classic experiment made cultured mouse leukemia cells develop more mature red-cell characteristics after DMSO exposure. This helped establish interest in differentiation, the process by which immature cells acquire specialized functions. [8]

Adverse effects & interactions

Topical treatment can irritate skin, while bladder instillation can cause discomfort and temporary chemical cystitis. Garlic-like breath or taste is characteristic. Hypersensitivity reactions can occur, and DMSO may alter the effects of other medicines. Its ability to cross skin makes the complete formulation relevant to exposure, not just the ingredient named on the front. [1]

The bladder-product label recommends eye monitoring because prolonged high exposures caused lens changes in animals, and warns about use in urinary-tract malignancy. Those animal findings should not be described as a proven rate of human cataracts. RIMSO-50 is specifically not an intravenous or intramuscular product. [1]

Human findings

Correcting scurvy is the clearest clinical use. Oral replacement is suitable for many patients; the prescription IV product is intended for short treatment when oral administration is not possible, sufficient or appropriate. [1]

For metastatic pancreatic cancer, adding IV ascorbate to gemcitabine/nab-paclitaxel produced median overall survival of 16 versus 8.3 months and progression-free survival of 6.2 versus 3.9 months. Thirty-six people were randomized and 34 treated. The unblinded trial stopped at an interim analysis after a strong efficacy signal, before its planned enrollment. [4]

Results differ in colorectal cancer. In VITALITY, 442 people received chemotherapy with or without IV vitamin C: median progression-free survival was 8.6 versus 8.3 months, without a significant overall advantage, and overall survival was similar. A prespecified RAS-mutated subgroup had longer progression-free survival, creating a focused question for subsequent research. [5] Earlier placebo-controlled oral trials also found no cancer benefit, including a 100-person colorectal study in patients without prior chemotherapy. [7] [6]

The topical BCC combination described in the DMSO review had encouraging biopsy-clearance results, but this evidence concerns that skin formulation and selected lesions. [8] A separate SCC-in-situ report remains an uncontrolled preprint. [9]

Outside cancer, the 872-person LOVIT trial tested IV vitamin C in adults with sepsis receiving vasopressors. Death or persistent organ dysfunction at day 28 occurred in 44.5% versus 38.5% with placebo. [10]

Laboratory findings & theoretical potential

Experiments in cancer-cell cultures found that pharmacological ascorbate could generate extracellular hydrogen peroxide and kill some cancer-cell lines while sparing tested normal cells. The response differed by cell type. [3] Human pharmacokinetic research established the major exposure difference between oral and IV administration. [2]

Adverse effects & interactions

High-dose exposure can cause oxalate kidney injury or stones, particularly with existing kidney problems. In G6PD deficiency it can trigger severe breakdown of red blood cells. Infusions can also interfere with glucose-meter and other laboratory readings. Kidney function, G6PD status and the reliability of glucose measurement therefore matter before interpreting an infusion's safety. [1] [11]

Interactions depend on the cancer regimen. Laboratory and animal work has raised concern about interference with bortezomib, while clinical combinations such as gemcitabine have been studied separately. [11] The small pancreatic trial reported no added overall toxicity. [4]

Benefits

Sermorelin can increase growth-hormone release, but a higher hormone level has not been shown to deliver reliable gains in adult strength, injury recovery or longevity. Limited evidence suggests improvement on selected cognitive tests in older adults; it does not establish prevention of dementia or better day-to-day function. Evidence for stimulating growth in children answers a different question. For confirmed growth-hormone deficiency, approved replacement has a clearer clinical role; age-related weakness also calls for resistance exercise, nutrition and evaluation of its cause.

Safety

Long-term safety in adults using sermorelin for wellness remains insufficiently defined. Increases in fasting glucose and insulin have been observed during pediatric treatment; those findings do not provide an adult risk estimate. Adult studies cannot reliably quantify uncommon serious effects.

Benefits

GHRP-2 raises growth hormone, but meaningful improvements in adult muscle strength, recovery or healthy aging have not been established. Even in children with growth-hormone deficiency, increased hormone release did not translate into better growth in controlled research. Appetite may increase, but that is not evidence of improved muscle function. Pediatric oral or nasal findings also cannot establish the effects of adult wellness injections. GHRP-2 has not demonstrated equivalent benefits to approved replacement for genuine growth-hormone deficiency.

Safety

Reported concerns include difficulty controlling blood sugar, infection, pancreatitis and deaths among critically ill recipients; those reports do not establish that GHRP-2 caused the events. Immune reactions and peptide impurities are additional concerns. The available evidence does not provide dependable rates for these risks in healthy adults or define the safety of long-term use. Oral, nasal and injected products should not be assumed to have the same risk profile.

Benefits

CJC-1295 can increase growth hormone and IGF-I, but improved strength, meaningful fat loss, faster injury recovery and longer life have not been established. Most applicable human evidence concerns the long-acting DAC form. Products sold as CJC-1295 without DAC are different preparations, and combinations with ipamorelin have not earned the benefits of the single-drug research by association. Approved replacement for diagnosed growth-hormone deficiency has clinical outcome evidence that CJC-1295 does not yet match.

Safety

Reported side effects include injection-site irritation, headache, flushing, diarrhea, nausea and transient low blood pressure or dizziness. Increased heart rate and widespread blood-vessel dilation have also been reported. Short-term studies cannot tell us the frequency of uncommon harms or the effects of prolonged hormone elevation. Product identity matters: the safety of one CJC-1295 preparation cannot be assumed for another, and immune reactions or impurities can add risk.

Benefits

Ipamorelin has not demonstrated reliable benefits for muscle growth, strength or recovery in people. Its main published clinical efficacy evidence concerns bowel recovery after surgery, where it did not clearly improve the principal or secondary outcomes compared with placebo. That does not establish a fitness benefit, and selective stimulation of a hormone pathway is not itself a useful health outcome. Claims for routine wellness use exceed the evidence available for this compound.

Safety

Safety for repeated subcutaneous wellness injections is not established. During intravenous postoperative use, reported events included nausea, vomiting, abdominal bloating, high blood sugar and low potassium. Serious complications, including two deaths, occurred, but whether ipamorelin contributed was unclear. These findings cannot provide a risk estimate for healthy users.

Benefits

GHRP-6 stimulates growth-hormone release, but improved strength, muscle function or recovery has not been established. Higher IGF-I levels reported during multi-drug hormone treatment cannot show what GHRP-6 contributed or whether patients gained a meaningful benefit. A laboratory change should not be presented as proof of healthier aging. Established care for confirmed hormone deficiency and exercise-based rehabilitation have clearer treatment goals and clinical evidence.

Safety

Potential effects on cortisol, reduced insulin sensitivity and higher blood sugar are important concerns. Immune reactions related to the peptide or its impurities are also possible. Human exposure data are too limited to estimate uncommon harms or establish long-term safety; results from single administrations or multi-hormone combinations do not resolve that uncertainty.

Benefits

Hexarelin can trigger growth-hormone release, but better adult body composition, strength and recovery remain unestablished. With repeated adult treatment, the hormone response weakened without a clear improvement in lean mass, body fat or bone density. Reports of faster height growth in children do not answer the adult performance question. Hexarelin has not demonstrated the clinical benefits expected from approved replacement in confirmed growth-hormone deficiency or from appropriate rehabilitation.

Safety

Available human studies reported few obvious adverse effects, but cannot reliably define common side-effect rates or uncommon serious harms. Long-term metabolic, cardiovascular and reproductive effects remain uncertain.

Benefits

Ibutamoren can increase fat-free mass, but that has not translated into dependable improvements in strength, daily function or recovery. It has not clearly reduced the deeper abdominal fat associated with metabolic risk. Raising growth hormone and IGF-I therefore should not be confused with restoring physical capability or extending healthy life. It is a nonpeptide drug, and its evidence does not establish an advantage over exercise-based rehabilitation or approved treatment of genuine endocrine deficiency.

Safety

Increased appetite, fluid retention and muscle pain are recognized problems. Blood sugar can rise and insulin sensitivity can worsen, particularly relevant for people with diabetes or prediabetes. A heart-failure signal in people recovering from hip fracture was serious enough to stop a study early. Longer exposure data have not resolved its overall benefit-risk balance for wellness use.

Benefits

Somatropin is established treatment for appropriately diagnosed growth-hormone deficiency. It promotes growth in affected children and can improve body composition and selected quality-of-life outcomes in deficient adults. Those benefits depend on the underlying diagnosis; normal age-related changes in hormone levels do not automatically establish deficiency. In healthy older adults, more lean mass has not consistently meant better function, and longer life or prevention of cardiovascular events has not been established. It is replacement therapy with specific indications, not a proven anti-aging treatment.

Safety

Swelling, joint or muscle discomfort, headaches and carpal-tunnel symptoms can occur, and glucose tolerance may worsen. Other important risks include increased pressure around the brain, severe allergic reactions and concerns about tumor growth or recurrence; active cancer is a contraindication. Long-term surveillance in treated adults with confirmed deficiency has been broadly reassuring about overall new cancer incidence, but does not establish safety in every population. Children need additional attention to hip problems, scoliosis and indication-specific risks. Treatment requires appropriate diagnosis and monitoring.

Benefits

Mecasermin helps children grow when severe primary IGF-1 deficiency prevents normal growth. Height gain is usually greatest early in treatment, with longer-term observations supporting continued growth in selected patients. It replaces a specific missing signal; it is not a general substitute for growth hormone, and growth hormone is not automatically effective when the main problem is primary IGF-1 deficiency. There is no established benefit for adult bodybuilding, recovery or longevity, and experimental IGF-1 LR3 is not interchangeable with this medicine.

Safety

Low blood sugar is a major risk and can cause seizures or loss of consciousness. Enlarged tonsils can interfere with breathing or sleep, and increased pressure around the brain, severe allergic reactions and childhood hip problems also require attention. Malignancies have been reported; a current or previous malignancy is a contraindication in the label. Years of pediatric follow-up provide more information than exists for experimental IGF-1 products, but do not establish that use outside the indicated population is safe.

Benefits

IGF-1 LR3 has not been shown in adequate human research to improve muscle strength, injury recovery or physical performance. Animal tissue growth does not establish those benefits in people. It is a modified molecule, not the approved IGF-1 medicine mecasermin, so evidence for treating severe pediatric IGF-1 deficiency does not validate LR3 for bodybuilding. There is no established clinical benefit or reliable effect size to compare with rehabilitation or other condition-specific care.

Safety

There is no dependable human safety profile for the exact LR3 molecule. Low blood sugar and unwanted growth signaling are biologically plausible concerns, but their likelihood and severity in users cannot be quantified from the available evidence. Its molecular modifications affect how it interacts with binding proteins, so mecasermin's side-effect rates cannot simply be assigned to LR3. Product identity, purity and potential immune reactions add further uncertainty.

Benefits

Injectable follistatin-344 protein has not demonstrated a clinical benefit for muscle growth, strength or recovery. Frequently cited improvements in walking involved experimental gene therapy in people with specific muscle diseases. Delivering a gene with a viral vector is different from injecting a commercial vial of follistatin protein, and results from one cannot validate the other. For patients with muscle disease, treatment depends on the diagnosis; for ordinary muscle building, an advantage over resistance training and nutrition remains unestablished.

Safety

Common side effects, serious harms and long-term risks of repeated protein injections have not been adequately characterized in people. Follistatin affects several growth and reproductive signaling pathways, leaving questions about effects beyond muscle. Safety observations from gene-transfer research do not resolve those questions for injected commercial protein.

Benefits

Elamipretide has a specific role in Barth syndrome, where it received accelerated approval to improve muscle strength in patients meeting the approved weight threshold. That evidence does not establish a general energy or longevity benefit. Results in primary mitochondrial myopathy have not shown a clear improvement in walking distance or fatigue. The strength gains supporting accelerated approval came from uncontrolled follow-up; the placebo-controlled study did not establish a significant strength benefit, so confirmation remains important. Otherwise unexplained fatigue still calls for identifying and treating its cause.

Safety

Injection-site redness, pain, itching and swelling are common. Allergic reactions can occur and have sometimes been serious enough to require emergency care. Longer follow-up in Barth syndrome adds useful information, but the number of patients is too small to estimate uncommon risks reliably. Its safety record in a rare mitochondrial disease should not be treated as evidence that repeated use in otherwise healthy people has an acceptable benefit-risk balance.

Benefits

Administered MOTS-c has not been shown to improve weight, exercise performance, metabolic health or lifespan in people. Studies measuring the peptide naturally present in the body do not establish that adding more will help. Research on a modified analogue also concerns a different intervention. For conditions such as obesity or osteoporosis, established treatments have demonstrated human weight-loss or fracture benefits that MOTS-c does not yet have.

Safety

There is no adequate human administration dataset to estimate common side effects, serious harms or risks from repeated exposure to MOTS-c itself. Potential immune reactions and peptide impurities remain concerns.

Benefits

Synthetic Epitalon has not demonstrated longer life, prevention of age-related illness or sustained relief of insomnia. Changes in melatonin-related measurements or laboratory telomerase activity do not establish those outcomes. Longer mortality reports frequently concern epithalamin, a pineal-gland extract that is different from the synthetic peptide. For persistent insomnia, cognitive behavioral therapy for insomnia and appropriately selected established treatments have evidence for outcomes patients can feel and measure.

Safety

Human safety reporting for synthetic Epitalon is limited; uncommon harms, interactions and the effects of repeated or prolonged use cannot be reliably quantified. Experience with the different gland extract, brief courses or another administration route does not establish the safety of repeated wellness use.

Human findings

For methemoglobinemia, the benefit is rapid correction of a dangerous problem with oxygen transport. The current intravenous product label reports a reduction of at least half in methemoglobin in 26 of 28 adults with paired measurements. This established indication should be kept separate from wellness uses. [1]

For severely low blood pressure caused by excessive vessel dilation, hospital studies suggest methylene blue can reduce the time patients need vasopressor medicines. A 91-person placebo-controlled septic-shock trial found a median 69 versus 94 hours to stopping vasopressors, with similar mortality. A separate 56-person postoperative vasoplegia trial reported fewer deaths, but that small, specific result cannot supply a general survival estimate for all shock. [7] [6]

For cognition, the most useful distinction is between changing a brain measurement and improving everyday function. In 26 healthy adults, a single oral exposure changed task-related brain activity. Memory responses improved approximately 7% within the methylene-blue group, but the change compared with placebo was not statistically significant. Alzheimer's research is more substantial but still exploratory: a 321-person oral methylthioninium-chloride trial reported a cognitive benefit in the moderate-disease subgroup at 24 weeks and further findings through 50 weeks. Those results concern Alzheimer's disease and a particular formulation, not established memory enhancement in healthy adults. [4] [5]

Other clinical uses need their own assessment. For encephalopathy after ifosfamide chemotherapy, some treated patients recovered quickly in a 12-case series, but untreated patients also recovered within 48 hours. For basal-cell skin cancer, an uncontrolled study reported complete responses in 11 of 17 completers after locally applied methylene blue plus light. This is photodynamic treatment of accessible lesions, not evidence that oral or intravenous methylene blue treats cancer throughout the body. [8] [9]

Laboratory findings & theoretical potential

The mitochondrial idea has a concrete experimental basis: methylene blue transferred electrons from NADH toward cytochrome c in laboratory models. Cancer experiments have also found changes in cellular energy use. In one glioblastoma study, methylene blue reduced cancer-cell proliferation in culture, yet did not produce tumor regression in the mouse xenograft experiment. These findings explain continuing research interest while showing why mitochondrial activity alone cannot predict an anticancer or longevity benefit in people. [3] [10]

Adverse effects & interactions

Potentially serious serotonin syndrome can occur with serotonergic medicines, opioids and dextromethorphan, an ingredient in some cough medicines. Methylene blue can cause hemolytic anemia, sometimes delayed. The licensed intravenous product is contraindicated in G6PD deficiency because severe hemolysis can occur. Severe allergy is possible, kidney impairment increases exposure, and pregnancy carries fetal risk. [1]

Claims that the drug permanently deposits in organs go beyond the cited distribution evidence. The pharmacokinetic study measured blood and urine in seven people and organ concentrations in rats; it demonstrated distribution and elimination, not permanent harmful deposits. Conversely, short hospital courses and single-exposure cognition studies cannot settle the safety of years of wellness use. Product, route, exposure and other medicines remain essential to interpreting the evidence. [2]

Benefits

Testosterone can improve sexual desire, sexual activity and other symptoms of testosterone deficiency in men who have symptoms and repeatedly confirmed low levels. Benefits are less consistent for erections and overall quality of life, especially when testosterone is only low-normal or symptoms have another cause. Treatment should therefore be judged by whether the relevant symptoms improve, not simply by a higher laboratory result. Testosterone has not been established as a way to prevent cardiovascular disease or extend life in men without hypogonadism.

Safety

Testosterone can increase red blood cell concentration and blood pressure, and it can suppress sperm production. Fertility plans, blood counts and blood pressure therefore matter before and during treatment. The strongest randomized cardiovascular evidence is reassuring about the combined risk of heart attack, stroke and cardiovascular death in appropriately selected men: events occurred in 7.0% with testosterone and 7.3% with placebo over an average 33 months of follow-up. However, atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone. These separate risks still require attention; the cardiovascular finding does not establish safety for every formulation, treatment duration or pattern of use.

Benefits

Menopausal hormone therapy is highly effective for hot flashes and night sweats, with relief that can continue while treatment is used. Estrogen can also treat menopause-related vaginal symptoms and help prevent bone loss; when vaginal symptoms are the only concern, local treatment may be sufficient. The appropriate treatment depends on the symptoms, age and time since menopause. These benefits support symptom-directed treatment, rather than using hormones solely to prevent heart disease or as a general anti-aging therapy.

Safety

Breast tenderness, spotting, bloating and headaches can occur. More serious risks depend on the regimen and the person's baseline risk: oral estrogen carries blood-clot and stroke concerns, while patches may have a lower clot risk. If the uterus is present, systemic estrogen generally needs accompanying endometrial protection to reduce uterine-cancer risk. Breast-cancer findings differ between estrogen alone after hysterectomy and estrogen combined with particular progestogens; the major randomized studies cannot be applied unchanged to every modern formulation. Personal history of cancer, clots, cardiovascular disease and unexplained bleeding helps determine whether treatment is appropriate.

Benefits

Vaginal prasterone can reduce moderate-to-severe pain during intercourse caused by menopause-related thinning of vaginal tissue. The benefit has been demonstrated in repeated controlled studies and applies to that formulation and purpose. Oral DHEA supplements have a different evidence base: they have not shown meaningful improvements in strength, physical performance, insulin sensitivity or quality of life in older adults. Taking DHEA by mouth should not be expected to reproduce the benefits of vaginal prasterone or provide an established anti-aging effect.

Safety

Vaginal discharge is the most frequently reported adverse effect of vaginal prasterone. In a year-long follow-up, about 14% reported discharge and 2% had an abnormal Pap result; those observations do not establish that the medicine caused every finding. Unexplained vaginal bleeding needs evaluation, and safety in women with a history of breast cancer has not been established. Oral DHEA has different hormone exposure and safety questions. A two-year controlled study did not detect major adverse effects, but it was too small to reliably assess uncommon harms.

Benefits

Gonadorelin can restore the hormone signals needed for ovulation in selected women whose infertility comes from inadequate signaling by the hypothalamus. Its established clinical use relies on a pump delivering carefully timed pulses and a pituitary gland that can respond. Published experience in women with functional hypothalamic amenorrhea reports ovulation in 96% of cycles and live birth in about 66% of treatment courses. Those results do not establish that occasional gonadorelin injections improve libido or preserve fertility during routine testosterone treatment.

Safety

Pump treatment can cause irritation, bruising, inflammation or infection around the infusion site. Ovarian overstimulation and multiple pregnancy are possible, even though appropriately selected pulsatile treatment often produces a single developing follicle. Monitoring the ovarian response is therefore part of treatment. Allergic reactions have also been reported. The safety experience is tied to specific fertility regimens and diagnoses; it does not establish the safety of prolonged, intermittent injections marketed for general hormone optimization.

Benefits

Kisspeptin-10 stimulates reproductive hormones, including LH and testosterone. A 2026 study found that intermittent administration maintained hormone responses for 12 days in healthy men. It has not yet been shown to produce lasting improvements in sexual symptoms, fertility or pregnancy outcomes. The pattern of exposure matters: responses can weaken with continuous stimulation, so an initial hormone increase does not establish a lasting treatment effect. Research on kisspeptin-54 concerns a different peptide and cannot be treated as proof that kisspeptin-10 works the same way.

Safety

Human exposure remains limited to short physiological studies, including a 12-day study. Evidence is insufficient to reliably estimate common side effects, uncommon serious events or risks from repeated use over months. Longer-term effects on reproductive signaling remain uncertain.

Benefits

hCG can stimulate the testes to produce testosterone and support sperm production in selected men with inadequate pituitary hormone signaling. This makes it useful when treating hypogonadotropic hypogonadism and fertility together, although some men also need FSH treatment. Preserving testosterone inside the testes during testosterone replacement is a biological effect; it does not by itself establish that fertility, pregnancy or live-birth outcomes will be preserved. The underlying diagnosis and the actual reproductive response determine whether treatment is working. hCG is also used in specialist ovulation-induction care, but it has no established weight-loss benefit.

Safety

Breast enlargement or tenderness, fluid retention, headache, mood symptoms and injection-site reactions can occur. Rare serious allergic reactions have been reported. Women receiving hCG as part of ovarian stimulation face a different set of risks, including ovarian hyperstimulation, multiple pregnancy and blood clots. Male safety information includes years of clinical follow-up, but the long-term studies are relatively small and do not reliably quantify uncommon harms. Monitoring should follow the condition being treated and the other hormones used with hCG.

Benefits

Clomiphene is an oral, nonpeptide medicine that can increase the body's own testosterone production when the hypothalamus, pituitary and testes can respond. In selected men with secondary hypogonadism, it can improve symptoms and some body-composition measures while maintaining reproductive hormone signaling. It is used off-label in men, and its evidence for symptoms and long-term outcomes is less extensive than for approved testosterone replacement. Improved testosterone or sperm measurements should not be treated as proof of improved pregnancy or live-birth rates.

Safety

Mood changes, breast tenderness and visual disturbances are important adverse effects. Blurred vision, spots or flashes require prompt clinical attention because some visual problems have persisted after the medicine was stopped. HDL cholesterol fell in one controlled male study. In one clinical series, about 8% of men treated beyond three years reported side effects; such observations cannot reliably exclude rare harms.

Benefits

Enclomiphene can raise testosterone while maintaining sperm concentrations in selected men with secondary hypogonadism. That is a useful biological distinction from testosterone replacement, which can suppress sperm production. However, the evidence has not established meaningful improvements in sexual symptoms, quality of life or live-birth outcomes. A better laboratory result therefore cannot be assumed to mean that a patient feels better or is more likely to conceive. Enclomiphene is one component of clomiphene, and the two do not have interchangeable evidence bases.

Safety

Headache and other adverse effects have been reported, while blood clots, cardiovascular events, visual effects, blood-cell concentration and prostate-related measurements remain areas of concern or uncertainty. A reported event does not prove that the medicine caused it, but available studies do not provide a dependable long-term risk estimate. Regulators have judged the balance of clinical benefit and safety insufficient for the proposed approval. Years of follow-up with clomiphene cannot be used as years of safety evidence for enclomiphene alone.

Benefits

Bremelanotide can improve low sexual desire and the distress it causes in premenopausal women with acquired, generalized hypoactive sexual desire disorder. Average improvements are modest, and treatment has not clearly increased the number of satisfying sexual events. This evidence applies when low desire is not primarily explained by another medical condition, a medication or relationship difficulties. It does not establish routine benefit for men, postmenopausal women or people seeking general sexual enhancement.

Safety

Nausea is the main drawback: it occurred in about 40% of treated women versus 1% receiving placebo, and about 8% stopped because of it. Flushing, headache, vomiting and injection-site reactions also occur. Temporary increases in blood pressure make known cardiovascular disease and uncontrolled hypertension important reasons not to use it. Skin darkening can persist after treatment stops. It can also affect absorption of some oral medicines and is not appropriate during pregnancy.

Benefits

Intranasal oxytocin has not demonstrated a reliable improvement in sexual desire or sexual function beyond placebo. Participants can feel better during treatment, but similar improvement has occurred with placebo, so the change cannot confidently be attributed to oxytocin. Its biological role in bonding and reproduction does not by itself establish a useful treatment for sexual symptoms. Established obstetric uses and research on vaginal formulations answer different questions from intranasal sexual-health treatment.

Safety

Sexual-health studies are too small and brief to reliably estimate uncommon adverse effects or the risks of prolonged intranasal treatment. Experience with oxytocin in obstetric care cannot establish the safety of repeated nasal use for sexual symptoms.

Benefits

Semax has preliminary human evidence suggesting improvements in some neurological recovery measures, but the findings do not establish a dependable benefit for healthy-person memory or concentration. Reported changes in BDNF are not proof of improved day-to-day cognition. In motor neuron disease, improvement in quality-of-life scores did not establish slower disease progression. Semax has not demonstrated that it can replace indicated stroke treatment, prevention of another stroke or rehabilitation.

Safety

Inconsistent adverse-event reporting prevents a reliable safety profile. Long-term repeated use, uncommon reactions and differences between nasal and injected products remain insufficiently studied. Potential immune reactions and product impurities are additional concerns.

Benefits

Selank has preliminary human evidence for anxiety relief, including use alongside an established antidepressant. However, the available findings do not establish reliable equivalence to first-line anxiety treatments, prevention of relapse or improved cognition in healthy people. Cognitive behavioral therapy and established anxiety medicines have a broader evidence base for symptom relief and ongoing care. The possible benefit of Selank remains a question for further clinical study.

Safety

Short courses have been described as well tolerated, but detailed adverse-event reporting, interaction information and long-term follow-up remain limited. Nasal evidence should not be applied to injections. Immune reactions and impurities are additional concerns for compounded preparations; their frequency is not reliably known.

Benefits

DSIP has not demonstrated reliable, lasting relief of insomnia. Reported improvements have been inconsistent, and controlled sleep measurements have not shown a convincing improvement in how well patients feel they sleep. Uncontrolled reports of benefit months later cannot establish that DSIP caused the change. Cognitive behavioral therapy for insomnia and approved sleep treatments have stronger evidence for patient-important outcomes.

Safety

Common side effects, uncommon serious risks and the safety of repeated use are not adequately characterized. Differences in formulation or administration route add uncertainty.

Benefits

Thymosin alpha-1 has human research in serious illnesses, but its benefits depend on the condition. It has not shown a clear survival benefit in the larger modern controlled sepsis evidence. Some findings in hepatitis B-related acute-on-chronic liver failure suggest improved survival without transplantation and merit further study. Neither result supports routine immune boosting in healthy people. Disease-specific antiviral treatment and established sepsis management remain central; changing immune measurements alone does not establish that a patient is healthier.

Safety

Short-course controlled sepsis evidence did not identify a clear difference in adverse outcomes compared with placebo. Longer experience in hepatitis provides additional information, but does not define the safety of indefinite immune enhancement in otherwise healthy people.

Benefits

Topical LL-37 has been studied for difficult venous leg ulcers, but an overall healing benefit remains unestablished. Early findings suggested faster healing; larger controlled evidence did not show more complete wound closure than standard wound care and placebo. Exploratory benefits in selected subgroups need confirmation. These topical findings do not establish that injecting LL-37 prevents infections or improves general immunity. Compression and appropriate wound management remain fundamental for venous ulcers.

Safety

Studied topical preparations were generally tolerated locally, but this does not establish injection or systemic safety. The frequency of serious effects, immune reactions and problems from repeated systemic exposure is not adequately known. Laboratory and animal findings also raise concerns about male reproduction and tumor-promoting effects in some tissues; these are potential risks, not demonstrated human outcomes.

Benefits

KPV has encouraging laboratory and animal findings related to inflammation, but adequate human benefit has not been established for inflammatory bowel disease, skin problems or wound healing. There is no reliable clinical effect size or evidence that it improves symptoms, healing or remission as well as established condition-specific treatments. This is a lack of human evidence, rather than proof from completed trials that KPV cannot work.

Safety

Human safety is largely unknown: no adequate dataset defines common side effects, serious harms, interactions or risks from repeated use of KPV itself. Laboratory and animal findings cannot establish its human safety profile.

Human findings

For susceptible infections, ivermectin can clear intestinal strongyloidiasis and markedly reduce the immature worms responsible for much of the illness in onchocerciasis. It does not kill adult Onchocerca worms, so reducing the parasite burden is different from permanently eliminating the infection. [1]

For inflammatory rosacea, two 12-week trials involving 1,371 adults found clear or almost-clear skin in approximately 38% to 40% using ivermectin cream, versus 12% to 19% using its vehicle. Forty-week extensions provided up to 52 weeks of topical experience. [3] [4]

Cancer benefit has not been established. NCT05318469 is testing oral ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer. The phase I/II, open-label, single-group study remained listed as recruiting in its August 5, 2026 update, with 34 participants planned and no results posted when checked for this review. Its main questions are tolerability and objective tumor response. [5]

RETRACTED STUDY: A 2026 ivermectin/mebendazole survey enrolled 197 people with cancer; 122 provided six-month follow-up. It claimed 48.4% reported tumor regression or no evidence of disease, while 25.4% reported side effects, predominantly mild. These were self-reports, without a comparison group, often alongside other treatments. The October 2026 retraction cited methodological and analytical problems. These figures describe the withdrawn paper's claims, not reliable response or safety estimates. [6] [7]

Laboratory findings & theoretical potential

A breast-cancer laboratory study proposed that ivermectin alters ATP-related purinergic signaling, promotes immunogenic cell death, and helps recruit immune cells into tumors. It reported improved mouse outcomes when combined with an immune checkpoint inhibitor. The paper received an Editorial Expression of Concern in June 2026. Its reported mechanisms and combination effects remain preclinical findings with an unresolved publication concern. [8] [9]

Adverse effects & interactions

Oral treatment can cause gastrointestinal symptoms and dizziness. Serious neurological toxicity, including confusion, seizures and impaired consciousness, and hepatitis or liver-enzyme abnormalities appear in postmarketing reports; their frequency cannot be calculated from those reports. Heavy Loa loa infection creates a particular risk of severe encephalopathy. Rare reports describe increased INR with warfarin, and severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. These spontaneous reports do not establish an incidence rate. [1]

The rosacea cream can cause local burning or irritation; allergic or contact dermatitis can occur. Its longer topical follow-up does not answer the safety question for repeated systemic cancer exposure. That distinction matters when discussing a proposed oral regimen with a clinician. [2] [4] [5]

Human findings

For susceptible intestinal worms, mebendazole has a clear clinical role. A randomized study of 295 children found that a chewable formulation cleared roundworm in 83.7% versus 11.1% with placebo at approximately 19 days. Whipworm clearance was lower, 33.9% versus 7.6%, showing why the particular parasite matters when judging likely benefit. [2]

The direct cancer evidence is much less favorable. In a phase IIa study of advanced gastrointestinal cancers that had progressed after available treatment, 11 people enrolled and 10 started mebendazole. All treated participants had progression; two stopped before the eight-week scan and eight stopped at that assessment. Only five reached the study's target blood concentration. This was a negative result for the approach tested, with variable absorption complicating exposure. No severe adverse effects were reported in this small study. [3]

A separate phase I study combined mebendazole with temozolomide in 24 adults with newly diagnosed high-grade glioma after radiation and initial chemotherapy. It provided feasibility and safety information, but without a comparison group it could not establish whether mebendazole improved survival. Two participants remained on treatment for more than five years. [4] [5]

The ivermectin/mebendazole cancer survey discussed in the ivermectin review is RETRACTED for methodological and analytical problems. Its self-reported outcomes cannot establish a contribution from mebendazole. Fenbendazole is a different drug. A separate three-patient fenbendazole series coauthored by William Makis was retracted after an undeclared conflict involving services related to the subject came to light. The notice did not establish fabrication of patient data. [7] [8]

Laboratory findings & theoretical potential

In lung-cancer cells, mebendazole disrupted microtubules, arrested cell division and triggered cell death. Mouse experiments also reported reduced tumor growth. These experiments explain the repurposing hypothesis. Whether adequate exposure can be achieved safely in people remains central to translating that hypothesis into a treatment. [6] [3]

Adverse effects & interactions

Short intestinal treatment can cause abdominal discomfort or other gastrointestinal symptoms. Higher or prolonged exposure has been associated with liver injury and reductions in white blood cells, including neutropenia and agranulocytosis. In the 24-person glioma combination study, four developed grade 3 liver-enzyme elevations at the highest exposure level, appearing during months two to five. [1] [4] [5]

The prescribing information also warns against combining mebendazole with metronidazole because severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported. For someone considering off-label use, an open clinical discussion should address other medicines, liver and blood-cell effects, and what outcome would justify continuing. [1]

Benefits

Topical GHK-Cu has limited evidence for cosmetic benefits. A preliminary eyebrow study suggests a possible growth effect, while controlled research after laser resurfacing did not demonstrate better objective wrinkle, redness or overall skin-quality outcomes. Evidence from multi-ingredient products also makes it difficult to know how much benefit comes from GHK-Cu itself. Broad claims about skin rejuvenation, wound healing or systemic longevity remain unestablished. For photoaging, sun protection and appropriate topical retinoids have a more developed clinical evidence base.

Safety

Direct human safety evidence mainly concerns short-term topical products, with limited information on uncommon reactions or long-term use; cosmetic formulations also differ. These findings cannot establish injection safety. No controlled long-term human safety study of injectable GHK-Cu was identified in this review, so systemic risks cannot be reliably quantified.

Benefits

Afamelanotide helps adults with erythropoietic protoporphyria spend more time in light without the severe pain caused by their condition. It also improves disease-related quality of life. In a controlled US study, median pain-free sunlight exposure over six months was about 69 hours with treatment versus 41 hours with placebo. This is a meaningful benefit for a specific photosensitivity disorder. It does not establish a role in cosmetic tanning or prevention of skin cancer, and light-protection measures remain necessary.

Safety

Nausea, implant-site reactions and changes in skin pigmentation are the main practical concerns. The implant can darken existing freckles and moles, so regular full-skin examinations are recommended. Serious allergic reactions, including anaphylaxis, have been reported after approval. Clinical follow-up extending over several years provides useful longer-term experience in people with this condition, but does not establish the safety of using the medicine for unrelated cosmetic purposes.

Benefits

Melanotan II can darken skin and trigger erections, but those effects have not established a favorable treatment option for cosmetic tanning or sexual dysfunction. The human evidence is sparse, with no dependable demonstration of sustained benefit that outweighs its risks. It has not been shown to prevent skin cancer or provide safe sun protection. It is also different from afamelanotide, whose evidence concerns a specific photosensitivity disorder, rather than routine tanning.

Safety

Reported effects include nausea, fatigue, sleepiness and spontaneous prolonged erections. Some erections have progressed to ischemic priapism, a medical emergency that can damage erectile tissue. Case reports establish that serious events can occur but cannot tell us how often. Adequate long-term data on skin-cancer risk and other systemic harms are missing.

Benefits

Teriparatide builds bone and reduces fracture risk in selected people with osteoporosis at high risk of breaking a bone. Its benefits include fewer spinal fractures, with evidence also supporting fewer nonspinal fractures in postmenopausal osteoporosis. In people with steroid-related osteoporosis, it reduced spinal fractures more than alendronate, although the difference in nonspinal fractures was not established. It is usually part of a planned treatment sequence that protects the bone gained after the course ends. These benefits do not establish a role in routine sports recovery or general anti-aging.

Safety

Dizziness, nausea, joint discomfort and a temporary drop in blood pressure after injection can occur. It can raise blood calcium and may be unsuitable for people with an underlying high-calcium disorder or relevant kidney-stone history. It is avoided in people with increased baseline risk of osteosarcoma, including certain bone diseases, skeletal cancers or prior radiation involving the skeleton. Long-term human surveillance has not found an increased osteosarcoma rate, but this is not evidence of decades of continuous treatment. Use beyond two years is reserved for patients who remain at or return to high fracture risk after clinical reassessment.

Benefits

Abaloparatide builds bone and reduces spinal and nonspinal fractures in postmenopausal women with osteoporosis at high fracture risk. Following it with a bone-preserving medicine such as alendronate helps maintain the benefit; the longer follow-up evidence evaluates that treatment sequence, not continuous abaloparatide. Its approval in men is supported by increased bone density rather than demonstrated fracture reduction. It is an established option for selected high-risk osteoporosis care, not a general treatment for tissue repair or athletic recovery.

Safety

Dizziness, nausea, palpitations and a drop in blood pressure after injection can occur. It can increase calcium in the blood or urine and may contribute to kidney-stone problems in susceptible people. Serious allergic reactions are possible. It should be avoided in people with increased baseline osteosarcoma risk, including certain bone diseases, skeletal cancers or previous radiation involving the skeleton. The animal bone-tumor finding has uncertain relevance to humans. Treatment beyond two years has not been evaluated and is not recommended in the current label; planning the next osteoporosis medicine is therefore part of its use.

Human findings

For diagnosed lead poisoning, calcium disodium EDTA can reduce blood lead and stored lead. Choice of chelator depends on severity and clinical circumstances; the product label describes both intravenous and intramuscular use. Reducing continuing exposure remains essential to the treatment plan. [1]

The original TACT trial randomized 1,708 people with a previous heart attack to a multicomponent EDTA-based infusion or placebo. Over a median 55 months, the composite of death, heart attack, stroke, coronary revascularization or hospitalization for angina occurred in 26% versus 30%, with hazard ratio 0.82. There was no significant overall-mortality reduction. The larger apparent benefit in participants with diabetes prompted a dedicated replication trial. [3] [5]

TACT2 randomized 1,000 people with diabetes and a previous heart attack; 959 received at least one infusion. Over a median 48 months, the primary composite occurred in 35.6% with chelation versus 35.7% with placebo, hazard ratio 0.93. Blood lead fell substantially, yet cardiovascular outcomes did not improve. [4]

Both trials studied an infusion mixture containing other ingredients, alongside usual cardiovascular care. Their findings describe that regimen, not isolated EDTA, calcium disodium EDTA for lead poisoning, or an oral wellness supplement. [3] [4]

Laboratory findings & theoretical potential

Metal binding provides a mechanism for treating a defined poisoning. Cardiovascular theories add another step: they assume that removing circulating metals will meaningfully change vascular injury or plaque behavior. These mechanisms motivated clinical trials that measured both metal levels and cardiovascular events. [1] [5] [4]

Adverse effects & interactions

Calcium disodium EDTA can injure the kidneys and increase zinc loss. Its label requires renal and electrolyte monitoring and warns about serious toxicity in lead encephalopathy. It can also interfere with zinc-containing insulin preparations. [1]

Disodium EDTA can abruptly lower blood calcium, potentially causing fatal complications; rapid infusion heightens this danger. The historical Endrate label describes emergency calcium-lowering use, not routine wellness treatment. [2] In TACT2, serious adverse events were similar between study groups under supervised conditions. [4]